We are honored to be included in the Top 10 In Vitro Diagnostics Solution Providers 2023 by the renowned MEDTECH OUTLOOK publication. Read the full interview here.
We are pleased to announce that Jan Wilke has decided to take over responsibility as Managing Director of BIT Analytical Instruments GmbH, effective on September 15, 2023.
Developing a new point of care instrument while keeping costs low will never be an unchallenging process for any engineering team. But with the use of an experienced team with cross-departmental collaboration and a manufacturing mindset, the device will be timely developed in the most cost-efficient manner for your clients.
Planet Innovation acquires BIT Group’s North American operations, doubling its medtech manufacturing capacity.
Startups and small/medium-sized enterprises in the IVD and medical device industry often do not have the appropriate resources and skills to produce and scale their IVD instruments in-house. As a result, they look for a contract manufacturing partner (CM) who takes over the production of the diagnostic devices.
We are pleased to announce that Ulrich Zimmermann has decided to take over responsibility as Managing Director of BIT Analytical Instruments GmbH and CFO Global of BIT Group effective on April 15, 2021.
BIT Hematology is specialized in designing, developing, and manufacturing hematology systems (instruments and exclusive reagents) for the low and mid-volume markets.
The regulatory and quality requirements in the IVD market are stringent and impact every step throughout a product’s life cycle.
We are pleased to inform you that BIT Group USA, Inc. will be consolidated into one location in Irvine/ CA. This will allow us to realize synergies and to expand our capabilities to better serve your growing needs.
In-Vitro Diagnostics (IVD) instruments are complex systems that require a transdisciplinary engineering approach that includes all disciplines, such as mechanical, electrical, fluidical, optical, software, as well as biological and chemical components.